Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Financial Statements

  Year Ending Dec 2016 (Update) Year Ending Dec 2015 (Update) Year Ending Dec 2014 (Update) Year Ending Dec 2013 (Update)
Net Sales -98.33 -52.58 -97.86 155.85
Gross Revenue 244.77 215.14 284.69
Revenue 146.44 162.56 186.83 155.85
Total Revenue 146.44 162.56 186.83 155.85
Cost of Revenue 35.84 27.69 27.04 28.58
Cost of Revenue, Total 35.84 27.69 27.04 28.58
Gross Profit 110.60 134.87 159.79 127.27
Selling/General/Administrative Expense 76.94 76.47 87.36 81.15
Labor & Related Expense 10.41 10.05 10.05 10.76
Selling/General/Administrative Expenses, Total 87.35 86.51 97.41 91.92
Research & Development 58.94 50.77 69.66 46.67
Amortization of Intangibles, Operating 25.95 38.32 24.29 20.07
Depreciation/Amortization 25.95 38.32 24.29 20.07
Purchased R&D Written-Off
Other Unusual Expense (Income) 7.40
Unusual Expense (Income) 7.40
Total Operating Expense 208.07 203.29 218.40 194.64
Operating Income -61.63 -40.73 -31.57 -38.79
Interest Expense - Non-Operating -9.69 -9.21 -8.72 -0.22
Interest Expense, Net Non-Operating -9.69 -9.21 -8.72 -0.22
Investment Income, Non-Operating
Interest/Investment Income, Non-Operating
Interest Income (Expense), Net Non-Operating 0.26 0.14 0.13 -1.98
Interest Income (Expense), Net-Non-Operating, Total -9.44 -9.07 -8.58 -2.19
Other Non-Operating Income (Expense) 0.24 -0.57 -3.38 4.34
Other, Net 0.24 -0.57 -3.38 4.34
Net Income Before Taxes -70.83 -50.38 -43.53 -36.64
Income Tax – Total -2.31 0.41 2.19 25.50
Income After Tax -68.51 -50.79 -45.72 -62.13
Minority Interest
Net Income Before Extraordinary Items -68.51 -50.79 -45.72 -62.13
Net Income -68.51 -50.79 -45.72 -62.13
Preferred Dividends
Total Adjustments to Net Income
Income Available to Common Excluding Extraordinary Items -68.51 -50.79 -45.72 -62.13
Income Available to Common Stocks Including Extraordinary Items -68.51 -50.79 -45.72 -62.13
Basic Weighted Average Shares 72.82 64.88 64.71 60.73
Basic EPS Excluding Extraordinary Items -0.94 -0.78 -0.71 -1.02
Basic EPS Including Extraordinary Items -0.94 -0.78 -0.71 -1.02
Dilution Adjustment --
Diluted Net Income -68.51 -50.79 -45.72 -62.13
Diluted Weighted Average Shares 72.82 64.88 64.71 60.73
Diluted EPS Excluding Extraordinary Items -0.94 -0.78 -0.71 -1.02
Diluted EPS Including Extraordinary Items -0.94 -0.78 -0.71 -1.02
DPS - Common Stock Primary Issue
Gross Dividends - Common Stock -- -- -- --
Stock-Based Compensation, Supplemental 10.55 1.97 1.76 12.78
Interest Expense, Supplemental 9.69 9.21 8.72 0.22
Depreciation, Supplemental 0.55 0.70 1.10 0.90
Total Special Items 7.40
Normalized Income Before Taxes -70.83 -50.38 -43.53 -29.24
Effect of Special Items on Income Taxes 2.59
Income Taxes Excluding Impact of Special Items -2.31 0.41 2.19 28.09
Normalized Income After Taxes -68.51 -50.79 -45.72 -57.32
Normalized Income Available to Common -68.51 -50.79 -45.72 -57.32
Basic Normalized EPS -0.94 -0.78 -0.71 -0.94
Diluted Normalized EPS -0.94 -0.78 -0.71 -0.94
Amortization of Intangibles, Supplemental 25.95 38.32 24.29 20.07
Rental Expense, Supplemental 1.50 1.70 1.90 1.20
Minority Interest, Supplemental
Research & Development Expense, Supplemental 58.94 50.77 69.66 46.67
Audit-Related Fees, Supplemental 1.23 1.40 1.54 1.63
Audit-Related Fees 0.19 0.13 0.02 0.25
Tax Fees, Supplemental 0.31 0.16 0.01 0.66
Gross Margin 75.52 82.97 85.53 81.66
Operating Margin -42.08 -25.06 -16.90 -24.89
Pretax Margin -48.36 -30.99 -23.30 -23.51
Effective Tax Rate
Net Profit Margin -46.78 -31.24 -24.47 -39.87
Normalized EBIT -61.63 -40.73 -31.57 -31.39
Normalized EBITDA -35.14 -1.71 -6.18 -10.42
Current Tax - Domestic -2.00 0.11 1.53 -8.36
Current Tax - Foreign 0.01 0.15 0.03 --
Current Tax - Local -0.22 0.01 0.13 -0.69
Current Tax - Total -2.21 0.27 1.68 -9.05
Deferred Tax - Domestic -0.09 0.11 0.50 36.18
Deferred Tax - Foreign -- -- -- --
Deferred Tax - Local -0.01 0.03 0.01 -1.64
Deferred Tax - Total -0.10 0.14 0.50 34.55
Income Tax - Total -2.31 0.41 2.19 25.50
Defined Contribution Expense - Domestic 0.95 1.12 1.03 0.86
Total Pension Expense 0.95 1.12 1.03 0.86

In millions of USD (except for per share items)

Back to top

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Copyright Nasdaq. Minimum 15 minutes delayed.